Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Raises $20M

NEW YORK (GenomeWeb News) – Cellular Dynamics has raised $20 million, the stem cell technologies firm said in a regulatory document filed on Wednesday.

In a Form D filed with the US Securities and Exchange Commission, the company, which filed to go public last month, did not say how it planned to use proceeds from the raise or disclose the investors, but said that eight investors participated in the offering. The securities offered were in the form of debt; options, warrants, or other rights to acquire another security; and security to be acquired upon exercise of option, option warrant, or other right to acquire security.

Cellular Dynamics announced in June its plans to raise a maximum aggregate of $57.3 million in its public offering. Based in Madison, Wis., it develops stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking.

In 2011, the company raised $30 million in a Series B Preferred Stock financing round, and $40.6 million 2010 in Series B private equity funding.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.